Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Reminder Invitation webcast Year-end report 2017

Press release 2018-01-29 Reminder: C-RAD Web Presentation Year-end Report 2017 Presentation of the report for the fiscal year 2017: Date: Thursday January 31, 2018 / kl. 11:00 Venue: Online Presentation Topic: C-RAD Year-end Report 2017 Procedure: Please register online through the website:   https://attendee.gotowebinar.com/register/7850384767697928451 After your registration, you will receive a confirmation via email. A recording of the presentation will be made accessible on the C-RAD website after the presentation. About C-RADC-RAD develops innovative

Invitation to presentation of Bulten’s Q4 report 2017

Bulten’s full year report for the period January –  December 2017 will be published on Thursday 8 February 2018 at approximately 13:30 CET.A presentation for analysts, media and investors will be held the same day at 15:30 CET. The report will be presented by Tommy Andersson, President and CEO and Helena Wennerström, Executive Vice President and CFO via audiocast. The presentation will be held in English and can be followed live via the link: https://tv.streamfabriken.com/bulten-q4-2017. It will also be possible to take part of the audiocast afterwards at the same address or at www.

BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy

· Favourable interim safety data reported across three phase II clinical trials with bemcentinib in combination with KEYTRUDA® (pembrolizumab) · Immune response demonstrated in AML patients treated with bemcentinib monotherapy in phase II clinical trial · Two posters featuring four of BerGenBio’s six phase II clinical trials with selective AXL inhibitor bemcentinib presented at the ASCO-SITC Clinical Immuno-Oncology SymposiumBergen, Norway, January 29, 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib as a potential

Pomegranate Investment portfolio update.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO ANY U.S. PERSONPomegranate Investment AB (publ) (“Pomegranate” or “the Company”) is pleased to report on a number of recent investments and significant developments among its portfolio companies in the last quarter of 2017 (Q4).  Pomegranate continues to invest in some of Iran’s most exciting growth companies which are driving economic growth and knowledge transfer in their sectors. Portfolio Company Event: Investment in Café Bazaar and Divar The Company has increased its indirect see-through economic interest in Café Bazaar group, Iran’

Agromino announces disposal of a non-core part of its elevator business

Agromino A/S (also the “Company”) announces that a share purchase agreement for the sale of its Ukrainian subsidiary – PrJSC “Novomirgorodskiy Elevator” (also the “Elevator”) for a price of USD 2.6 million has been signed. The Elevator, located in Kirovograd region, Ukraine, has a total usable storage capacity of 107,700 tonnes, out of which concrete bins hold 72 thousand tonnes of grains. By the date of this press release the Company has already received prepayment in the amount of USD 450 thousand, and the remaining part of the purchase price will be received by the Company not later

Getinge publishes year-end report for January-December 2017

“We see increased sales, order intake and strengthened underlying gross margin in the fourth quarter,” says Mattias Perjos, President & CEO of Getinge. “Customer focus and successful sales initiatives contributed to higher organic order intake and sales.” All sales regions and business areas reported organic growth in their order intake for the fourth quarter. Net sales increased organically in the Acute Care Therapies and Surgical Workflows business areas and in the Americas and APAC sales regions, while sales in EMEA were impacted by the lower order intake of prior quarters. “

Arjo year-end report January-December 2017

”We have seen a positive development in several markets in the fourth quarter, and in addition we see yet another positive quarter for our US rental business. However, the development in the UK remained challenging with low NHS investments. When adjusted for the DVT situation in the US in the fourth quarter 2016, we see a positive net sales development in the quarter. The activities we are carrying out are paying off and I look forward to continuing to deliver on the plans that we have announced”, says Joacim Lindoff, President & CEO October-December 2017 in brief • Net sales fell -4.

Handelsbanken’s year-end report for January-December 2017 will be presented on February 7

Handelsbanken will present its results for January­‑December 2017 in Stockholmon February 7, 2018, at 9:00 a.m. CET, at a meeting with the media and analysts. The year-end report for January‑December 2017 will be published at 7:00 a.m. CET, on February 7, 2018. A telephone conference will be held at 11:00 a.m. CET (5:00 a.m. EST), whenRolf Marquardt, CFO, will present and comment on the results. There will also be timefor questions from the participants. UK number: +44 203–364 5374Swedish number: +46 8–505 564 74US number: +1 855–753 2230 Instructions1.    Dial +xx

Pihlajalinna acquires Linnan Klinikka in Hämeenlinna

Pihlajalinna Plc     Press release       29 January 2018 at 9:00 a.m. Pihlajalinna acquires Linnan Klinikka in Hämeenlinna Pihlajalinna is acquiring the entire share capital of the Linnan Klinikka Oy in Hämeenlinna from its current owners. The transaction will be completed on 2 February 2018. Linnan Klinikka will become a part of the Pihlajalinna’s chain of private clinics. With this acquisition of the Linnan Klinikka, Pihlajalinna is realising its national expansion plan before the implementation of the healthcare and social welfare reform. The private clinic and hospital of the

Segmentation and quantification of brain tissue, and industry first myelin volume measurements in SyMRI now FDA cleared.

The new regulatory clearance from the American Food and Drug Administration, FDA, concerns the SyMRI NEURO product package. Combined with FDA's clearance from August 2017, this means SyMRI as a whole can now be offered to clinics and hospitals on the US market.SyMRI NEURO is the next level of quantitative MR. The unique technology measures the absolute tissue properties of the brain and provides quantitative data, automatic segmentation and adjustable contrast images. This provides more information to the clinician and offers objective decision support for diagnosis and follow-up of the

Drilling Commences at Dussafu

Oslo, 29 January 2018 – Panoro Energy ASA (“PEN”, OSE ticker code) is pleased to announce that drilling has just commenced on the DTM-2H production well on the Tortue oil field, located offshore Gabon and part of the Dussafu Marin Production Sharing Contract (“PSC”).  The well is being drilled with the Borr Norve jack-up rig. Tortue is an offshore field located in the southern part of Gabon and situated in a water depth of 116 metres approximately 50 km from the coast. Panoro Energy holds an 8.33% interest in the Dussafu Marin PSC, operated by BW Energy Dussafu BV. The Tortue field

Karessa Pharma announces today that the company's license has been reinforced through patent granted in Europe

The European Patent Office (EPO) has issued a granted patent regarding patent application for the use and formulation of buccal films based on alginate. The grant of the patent with number 1976562 will be published by EPO's European Patent Bulletin on 21st of February 2018.Karessa Pharma AB ("Karessa") develops effective pharmaceuticals for treatment of erectile dysfunction based on a patented buccal film technology with a matrix based on alginate. The Film patent, owned by Uppsalagruppen AB with an exclusive, eternal, royalty-free license to Karessa in the therapeutic area of erectile

EQT Mid Market to sell I-MED Radiology Network to Permira

· EQT Mid Market to sell diagnostic imaging service company I-MED Radiology Network to the Permira funds · EQT Mid Market invested in I-MED in April 2014 together with Singaporean Sovereign Wealth fund GIC and Caisse de dépôt et placement du Québec, one of Canada’s leading institutional fund managers · During EQT Mid Market’s ownership, I-MED has had substantial organic growth, increased scale through multiple add-on acquisition, invested significantly in new equipment and technology and enhanced operating efficiency The EQT Mid Market fund (“EQT Mid Market”) has, together with co-

Cognosec AB (Publ): Cognosec AB files registration statement with SEC for a proposed Level 1 ADR Offering

PRESS RELEASE   London, 27th January 2018 Cognosec AB files registration statement with SEC for a proposed Level 1 ADR OfferingLondon, United Kingdom, January 27, 2018 - Cognosec AB announced today that it has filed a registration statement on Form F-6 with the U.S. Securities and Exchange Commission relating to the establishment of a Level 1 American Depositary Receipt (ADR) issuance program. The Bank of New York Mellon has been appointed as the Company`s depositary bank for this program. A registration statement relating to these American Depositary Receipts has been filed with

Höegh LNG : Höegh LNG Partners LP announces "at the market" equity raising programme

Hamilton, Bermuda, 26 January 2018 - Höegh LNG Partners LP ("HMLP" or "the partnership") today filed a prospectus supplement with the Securities and Exchange Commission ("SEC") to inform that it has entered into a sales agreement with B. Riley FBR, Inc. (the agent), relating to its common units, as well as its 8.75% Series A Preferred Units (together "the offered units"). In accordance with the terms of the sales agreement, HMLP may offer and sell, from time to time, new offered units having an aggregate offering price of up to USD 120 million through the agent in an "at the market"

AZ Reports Phase III Results for PT010 in COPD - Amendment

26 January 2018 18:20 GMT    The following amendments have been made to the 'AZ Reports Phase III Results for PT010 in COPD' announcement released on 26/01/2018 at 07:00. These amendments are to correct text, delineating the PT010 superiority primary endpoints from the comparator PT009 non-inferiority primary endpoints: · Subhead amended from "eight out of nine" to "six out of seven." · First sentence amended from "in eight out of nine" to "compared with dual combination therapies in six out of seven." · Body copy amended to include: "In total, eight of the nine

ChromoGenics secures funding for offensive market expansion – rights issue subscribed to 81.3 percent

ChromoGenics AB (publ) raises approximately SEK 33 million in the recently completed rights issue, securing funding for the company's target for an offensive market expansion over the next 12 months.Outcome of the rights issueIn total, 18.866.458 units were subscribed for, corresponding to approximately 81.3% of the total offer in the rights issue. 7.952.557 units, corresponding to approximately 34.3% of the offer, were subscribed for with unit/subscription rights. 1.437.297 units, corresponding to approximately 6.2% of the offer, were subscribed for without unit/subscription rights. 9.

Making an Impact

Impressions, implants, ortho aligners and sleep appliances can all make an impact on the lives of patients. All of these dental procedures and appliances are possible with a great intraoral scanner. The definition of CAD/CAM means the computer-aided design and computer-aided manufacture of a product used to turn designs into physical parts. For the dental profession, we normally think of restorations such as crowns, inlays, and onlays. Thinking outside the box and expanding the capabilities of CAD/CAM requires vision and ingenuity. Digital dentistry is the not only the future but also

Beaumont Hospital, US, extends RayStation to Photon Therapy

Beaumont Hospital in Royal Oak, Michigan, has chosen to make a significant extension to its RayStation installation, which will include photon therapy in addition to proton. RayStation will be used for photon planning at Beaumont Hospital in Dearborn, where new linacs will be commissioned for the system. The purchase also includes additional functionality and licenses for proton therapy at Beaumont Hospital, Royal Oak.The nationally recognized cancer program at Beaumont is based on the latest treatment technologies. Beaumont initially purchased RayStation for proton therapy in 2014, and

Resolutions at the Extraordinary General Meeting in Medivir on 26 January 2018

The Extraordinary General Meeting in Medivir Aktiebolag (publ) (“Medivir”) on 26 January 2018 resolved, among other things, on the following; The meeting resolved to authorize the board, for the period up to the annual general meeting 2018, to resolve to issue new shares of series B with deviation from the shareholders’ pre-emptive rights. The total number of shares that may be issued under the authorization shall total not more than 20 percent of the number of shares of series B issued as per the date of the meeting. The meeting further resolved on an additional issue authorization

Dome Energy AB gives drilling update; Glaze 11-11 is successful

Dome Energy AB.  (herein after “Dome” and/or “the Company”) announces that the drilling of the first well in Indiana this winter is expected to be successful. The Glaze 11-11 is drilled to its target depth of 4,100 ft., and logging indicates net pay zone of more than 130 ft. The well will be cased over the next few days and completed and put on production during February. The rig will now move on to our second well of the program, Glaze 11-12. Estimated drill start is next week. Paul Mørch, CEO: “We are very satisfied with the indications we see in the logging

HiQ helps Trafi create a prototype of a Digital Driving License

HiQ and Great Apes have designed a technical prototype for a Digital Driving License (DDL), together with the Finnish Transport Safety Agency, Trafi.HiQ, with expertise using technology to simplify people’s everyday life, developed the prototype with focus on simplicity and security.The Digital Driving License has two main information security levels: visual security and backend security. The visual security level uses a gyroscope-connected digital watermark combined with continuously animated background that supports interaction to prevent motion capture frauds. User information and

LINK Mobility Group ASA signs Term Sheet regarding acquisition of SMS.it in Italy, the first Mobile Internet Services Provider

LINK Mobility Group ASA ("LINK"), one of Europe's leading and fastest growing providers of B2C mobile messaging and mobile services, has entered into a term sheet regarding the acquisition of Italian mobile messaging company SMS Italia Srl ("SMS.it"). SMS.it is one of the leading mobile messaging providers in Italy. Established in 1996, SMS.it was the first in the world to provide mobile Internet services and the first mobile messaging provider on a global scale. Located in Milan, with offices in Bologna, SMS.it is a mobile operator owning an independent mobile network, fixed network,

There are no items matching the current filter
There are no more items matching the current filter
Back to top